As generally seen in other treatments, a decline in post-treatment tumor marker level is associated with better efficacy of immunotherapy in advanced HCC; the AFP response at 6 weeks after atezolizumab plus bevacizumab initiation especially seemed to be a potential surrogate biomarker for prognosis [43,44,45]. This evidence concerns the gene AFP and hepatocellular carcinoma.